title: Fasting glucose level reduction induced by imatinib in chronic myeloproliferative disease with TEL-PDGFRβ rearrangement and type 1 diabetes.
authors.forename: Adriano
authors.initials: A
authors.lastname: Salaroli
authors.forename: Giuseppina
authors.initials: G
authors.lastname: Loglisci
authors.forename: Alessandra
authors.initials: A
authors.lastname: Serrao
authors.forename: Giuliana
authors.initials: G
authors.lastname: Alimena
authors.forename: Massimo
authors.initials: M
authors.lastname: Breccia
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001549:Benzamides; D001786:Blood Glucose / Q000032:analysis; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D004347:Drug Interactions; D016903:Drug Monitoring; D015321:Gene Rearrangement; D006801:Humans; D007003:Hypoglycemia / Q000139:chemically induced* / Q000517:prevention & control; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000068877:Imatinib Mesylate; D007328:Insulin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D009196:Myeloproliferative Disorders / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics; D015514:Oncogene Proteins, Fusion / Q000235:genetics* / Q000378:metabolism; D010879:Piperazines / Q000009:adverse effects* / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D011743:Pyrimidines / Q000009:adverse effects* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin; D015514:Oncogene Proteins, Fusion; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; C120888:TEL-PDGFRbeta fusion protein, human; D000068877:Imatinib Mesylate